Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer
Siavash Foroughi, Ryan A Hutchinson, Hui-li Wong, Michael Christie, Ahida Batrouney, Rachel Wong, Margaret Lee, Jeanne Tie, Antony Wilks Burgess, Peter Gibbs
Growth Factors | TAYLOR & FRANCIS LTD | Published : 2021
For patients with metastatic colorectal cancer (mCRC), epidermal growth factor receptor (EGFR) inhibitors are limited to patients with RAS wild-type tumours. Not all patients will benefit from treatment and better predictive biomarkers are needed. Here we investigated the prognostic and predictive impact of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG). Expression levels were assessed by immunohistochemistry on 99 KRAS wild-type tumours. AREG and EREG positivity was seen in 49% and 50% of cases, respectively. No difference in expression was observed by primary tumour side. There was no significant difference in OS by AREG or EREG expression. In the subset of patients who receive..View full abstract
S.F. is supported by an Australian Government Research Training Program Scholarship.